Literature DB >> 2176944

Skeletal muscle metabolism in heart failure: a 31P nuclear magnetic resonance spectroscopy study of leg muscle.

L Arnolda1, M Conway, M Dolecki, H Sharif, B Rajagopalan, J G Ledingham, P Sleight, G K Radda.   

Abstract

1. The gastrocnemius muscle of seven patients with mild to moderate chronic heart failure and of five healthy control subjects was studied using 31P nuclear magnetic resonance spectroscopy. Spectra were collected at rest and during an incremental, symptom-limited, exercise protocol. Blood flow was measured in the same study during brief interruptions to exercise. 2. The phosphocreatine/(phosphocreatine plus inorganic phosphate) ratio was lower in patients with heart failure than in control subjects at an exercise rate of 1.5 W, although intracellular pH and blood flow were similar. 3. The cytosolic free adenosine 5'-diphosphate concentration was markedly increased in patients with heart failure exercising at 1.5 W compared with control subjects exercising at the same workload. 4. Although the maximum workload achieved by patients with heart failure was less than half of that reached by control subjects, the pH and the phosphocreatine/(phosphocreatine plus inorganic phosphate) ratio were lower in patients with heart failure at maximal load. Blood flow was less at maximal exercise in patients with heart failure than in control subjects in keeping with the reduced work load. 5. The phosphocreatine depletion induced in the gastrocnemius muscle by exercise was more severe than previously described in the forearm of patients with heart failure. 6. Metabolic abnormalities in skeletal muscle may contribute to exercise intolerance in heart failure, particularly during submaximal exercise.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2176944     DOI: 10.1042/cs0790583

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  9 in total

1.  Dissociation between muscle metabolism and oxygen kinetics during recovery from exercise in patients with chronic heart failure.

Authors:  A Hanada; K Okita; K Yonezawa; M Ohtsubo; T Kohya; T Murakami; H Nishijima; M Tamura; A Kitabatake
Journal:  Heart       Date:  2000-02       Impact factor: 5.994

2.  Magnetic resonance spectroscopy in congenital heart disease.

Authors:  V M Miall-Allen; G J Kemp; B Rajagopalan; D J Taylor; G K Radda; S G Haworth
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

Review 3.  Exercise training as therapy for chronic heart failure.

Authors:  N G Uren; D P Lipkin
Journal:  Br Heart J       Date:  1992-06

4.  Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes.

Authors:  G Vescovo; M Volterrani; R Zennaro; M Sandri; C Ceconi; R Lorusso; R Ferrari; G B Ambrosio; L Dalla Libera
Journal:  Heart       Date:  2000-10       Impact factor: 5.994

5.  Abnormalities in exercising skeletal muscle in congestive heart failure can be explained in terms of decreased mitochondrial ATP synthesis, reduced metabolic efficiency, and increased glycogenolysis.

Authors:  G J Kemp; C H Thompson; J R Stratton; F Brunotte; M Conway; S Adamopoulos; L Arnolda; G K Radda; B Rajagopalan
Journal:  Heart       Date:  1996-07       Impact factor: 5.994

6.  Evaluation of myocardial energy status in vivo by NMR spectroscopy.

Authors:  A M Seymour
Journal:  Basic Res Cardiol       Date:  1993 Sep-Oct       Impact factor: 17.165

Review 7.  Exercise for patients with congestive heart failure.

Authors:  R J Shephard
Journal:  Sports Med       Date:  1997-02       Impact factor: 11.136

8.  Potential of phosphorus nuclear magnetic resonance spectroscopy in studies of the energy metabolism of skeletal muscles.

Authors:  S K Ternovoi; T N Veselova; V E Sinitsin
Journal:  Neurosci Behav Physiol       Date:  2003-09

9.  Human skeletal muscle digitalis glycoside receptors (Na,K-ATPase)--importance during digitalization.

Authors:  T A Schmidt; P Holm-Nielsen; K Kjeldsen
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.